<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03785197</url>
  </required_header>
  <id_info>
    <org_study_id>FASTA</org_study_id>
    <nct_id>NCT03785197</nct_id>
  </id_info>
  <brief_title>Effects of a Clinical Dietary Intervention During Inpatient Treatment</brief_title>
  <acronym>FASTA</acronym>
  <official_title>Effects of a Clinical Dietary Intervention During Inpatient Treatment (Modified Fasting in Metabolic Syndrome, Osteoarthritis of the Hip or Knee, Rheumatoid Arthritis and Fibromyalgia)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is a scientific and prospective documentation of the clinical&#xD;
      effects of an inpatient treatment at the Immanuel Hospital of Berlin, in the department for&#xD;
      complementary and integrative medicine, with the use of a modified fasting regime. A pre- and&#xD;
      post- as well as group comparisons are planned. Patients that are admitted to the inpatient&#xD;
      department for metabolic syndrome, osteoarthritis of the hip or knee, rheumatoid arthritis&#xD;
      and fibromyalgia will be enrolled in the study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At the beginning, during and at the end of the treatment at the inpatient department routine&#xD;
      blood parameters, anthropometric parameters and certain scores and parameters specific to the&#xD;
      different conditions will be measured. Questionnaires will be filled out by patients before&#xD;
      and after the treatment as well as 3, 6 and 12 months after leaving the inpatient department.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 1, 2018</start_date>
  <completion_date type="Anticipated">March 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Fibromyalgia Impact Questionnaire (FIQ)</measure>
    <time_frame>Change Baseline, 2 weeks, 3 months, 6 months, 12 months</time_frame>
    <description>Questionnaire; The FIQ is scored in such a way that a higher score indicates a greater impact of the syndrome on the person. Each of the 10 items has a maximum possible score of 10. Thus the maximum possible score is 100. The average FM patient scores about 50, severely afflicted patients are usually 70 plus.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease Activity Score 28 (DAS 28)</measure>
    <time_frame>Change Baseline, 2 weeks, 3 months, 6 months, 12 months</time_frame>
    <description>Questionnaire with Clinical Examination; Change from Baseline in the DAS-28, range from 2.0 to 10.0 while higher values meaning a higher disease activity and below of 2.6 meaning remission</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Health Assessment Questionnaire (HAQ)</measure>
    <time_frame>Change Baseline, 2 weeks, 3 months, 6 months, 12 months</time_frame>
    <description>Questionnaire; Change from Baseline in the HAQ, range from 0 to 3 while higher values meaning a higher grade of disability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)</measure>
    <time_frame>Change Baseline, 2 weeks, 3 months, 6 months, 12 months</time_frame>
    <description>Questionnaire consisting of 24 items divided into 3 subscales: Pain (5items), Stiffness (2 items), Physical Function (17 items). The test questions are scored on a scale of 0-4, which correspond to: None (0), Mild (1), Moderate (2), Severe (3), and Extreme (4).&#xD;
The scores for each subscale are summed up, with a possible score range of 0-20 for Pain, 0-8 for Stiffness, and 0-68 for Physical Function. Higher values meaning a higher grade of disability.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Summary of Diabetes Self Care Activities Measure (SDSCA)</measure>
    <time_frame>Change Baseline, 2 weeks, 3 months, 6 months, 12 months</time_frame>
    <description>Questionnaire; 11 items with each item scored on a scale of 0-7.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain on Visual Analogue Scale (VAS)</measure>
    <time_frame>Change Baseline, 2 weeks, 3 months, 6 months, 12 months</time_frame>
    <description>Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Anxiety and Depression Scale (HADS)</measure>
    <time_frame>Change Baseline, 2 weeks, 3 months, 6 months, 12 months</time_frame>
    <description>Questionnaire; HADS: Assessing full scale, range 0-42, lower score meaning a better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perceived Stress Scale (PSS)</measure>
    <time_frame>Change Baseline, 2 weeks, 3 months, 6 months, 12 months</time_frame>
    <description>Questionnaire; Change from Baseline in the PSS, range from 0 to 4 in each item. Scores are obtained by reversing responses (e.g., 0 = 4, 1 = 3, 2 = 2, 3 = 1 &amp; 4 = 0) to the positively stated items and then summing across all scale items while higher values meaning a higher grade of perceived stress.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (WHO-5)</measure>
    <time_frame>Change Baseline, 2 weeks, 3 months, 6 months, 12 months</time_frame>
    <description>Questionnaire; Change from Baseline in the WHO-5, range from 0 to 100 % while higher values meaning a higher grade of well-being</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body-Mass-Index (BMI)</measure>
    <time_frame>Change Baseline, 2 weeks</time_frame>
    <description>Anthropometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>Change Baseline, 2 weeks</time_frame>
    <description>Measuring systolic and diastolic blood pressure in mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24h-Blood pressure</measure>
    <time_frame>Change Baseline, 2 weeks</time_frame>
    <description>Measuring systolic and diastolic blood pressure with Device &quot;Mobil-O-Graph&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood count</measure>
    <time_frame>Change Baseline, 2 weeks</time_frame>
    <description>Laboratory test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glomerular filtration rate (GFR)</measure>
    <time_frame>Change Baseline, 2 weeks</time_frame>
    <description>Laboratory test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood lipids</measure>
    <time_frame>Change Baseline, 2 weeks</time_frame>
    <description>triglycerides (mmol/L), total cholesterol (mmol/L), LDL (mmol/L), HDL (mmol/L), fasting glucose (mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRP</measure>
    <time_frame>Change Baseline, 2 weeks</time_frame>
    <description>CRP in milligram per liter (mg/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver enzymes (GOT, GPT)</measure>
    <time_frame>Change Baseline, 2 weeks</time_frame>
    <description>Hepatic transaminases (GPT, GOT in U/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stepcounter</measure>
    <time_frame>Change Baseline, 2 weeks</time_frame>
    <description>With Device &quot;Everion&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate Variability</measure>
    <time_frame>Change Baseline, 2 weeks</time_frame>
    <description>With Device &quot;Faros 180&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate</measure>
    <time_frame>Change Baseline, 2 weeks</time_frame>
    <description>With Device &quot;Everion&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Oxygenation</measure>
    <time_frame>Change Baseline, 2 weeks</time_frame>
    <description>With Device &quot;Everion&quot;</description>
  </secondary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Metabolic Syndrome</condition>
  <condition>Osteoarthritis, Hip</condition>
  <condition>Osteoarthritis, Knee</condition>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Fibromyalgia</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Prolonged modified fasting</intervention_name>
    <description>The prolonged modified fasting is a dietary intervention with abstinence from solid foods and a caloric intake of 100-400 kcal through juices and vegetable broths</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, serum, urine&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Regular hospitalised patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The patient is consents to participating in the trial during the first 24h of his or&#xD;
             her stay in the inpatient naturopathic department of the Immanuel Hospital.&#xD;
&#xD;
          -  Written informed consent is given&#xD;
&#xD;
          -  The referral diagnosis is one of the following: diabetes mellitus type 2/metabolic&#xD;
             syndrome, osteoarthritis of the hip, osteoarthritis of the knee, rheumatoid arthritis,&#xD;
             fibromyalgia.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Language barries to understanding the instructions of the study personnel&#xD;
&#xD;
          -  Dementia or other strong cognitive impairment&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Taking part in another study at the same time&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Michalsen, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Study Principal Investigator</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Immanuel Hospital</name>
      <address>
        <city>Berlin-Wannsee</city>
        <state>Berlin</state>
        <zip>14109</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>December 20, 2018</study_first_submitted>
  <study_first_submitted_qc>December 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2018</study_first_posted>
  <last_update_submitted>May 10, 2021</last_update_submitted>
  <last_update_submitted_qc>May 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Andreas Michalsen</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>fasting</keyword>
  <keyword>natural therapies</keyword>
  <keyword>prolonged fasting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
    <mesh_term>Osteoarthritis, Hip</mesh_term>
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

